240 related articles for article (PubMed ID: 33547983)
1. Tumor and Systemic Immunomodulatory Effects of MEK Inhibition.
Dennison L; Mohan AA; Yarchoan M
Curr Oncol Rep; 2021 Feb; 23(2):23. PubMed ID: 33547983
[TBL] [Abstract][Full Text] [Related]
2. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
[TBL] [Abstract][Full Text] [Related]
3. MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.
Yarchoan M; Mohan AA; Dennison L; Vithayathil T; Ruggieri A; Lesinski GB; Armstrong TD; Azad NS; Jaffee EM
PLoS One; 2019; 14(10):e0224600. PubMed ID: 31671149
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibitors for the treatment of non-small cell lung cancer.
Han J; Liu Y; Yang S; Wu X; Li H; Wang Q
J Hematol Oncol; 2021 Jan; 14(1):1. PubMed ID: 33402199
[TBL] [Abstract][Full Text] [Related]
5. Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade.
Shin MH; Kim J; Lim SA; Kim J; Lee KM
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260561
[TBL] [Abstract][Full Text] [Related]
6. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in
Sun C; Fang Y; Yin J; Chen J; Ju Z; Zhang D; Chen X; Vellano CP; Jeong KJ; Ng PK; Eterovic AKB; Bhola NH; Lu Y; Westin SN; Grandis JR; Lin SY; Scott KL; Peng G; Brugge J; Mills GB
Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566428
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
9. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
10. MEK inhibitors under development for treatment of non-small-cell lung cancer.
Kim C; Giaccone G
Expert Opin Investig Drugs; 2018 Jan; 27(1):17-30. PubMed ID: 29216787
[TBL] [Abstract][Full Text] [Related]
11. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
12. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
[TBL] [Abstract][Full Text] [Related]
13. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
14. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
Peng DH; Rodriguez BL; Diao L; Gaudreau PO; Padhye A; Konen JM; Ochieng JK; Class CA; Fradette JJ; Gibson L; Chen L; Wang J; Byers LA; Gibbons DL
Nat Commun; 2021 May; 12(1):2606. PubMed ID: 33972557
[TBL] [Abstract][Full Text] [Related]
15. MEK inhibitors in oncology: a patent review (2015-Present).
Mahapatra DK; Asati V; Bharti SK
Expert Opin Ther Pat; 2017 Aug; 27(8):887-906. PubMed ID: 28594589
[TBL] [Abstract][Full Text] [Related]
16. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
17. Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos PI; Solit DB
Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
[TBL] [Abstract][Full Text] [Related]
18. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.
Hatzivassiliou G; Haling JR; Chen H; Song K; Price S; Heald R; Hewitt JF; Zak M; Peck A; Orr C; Merchant M; Hoeflich KP; Chan J; Luoh SM; Anderson DJ; Ludlam MJ; Wiesmann C; Ultsch M; Friedman LS; Malek S; Belvin M
Nature; 2013 Sep; 501(7466):232-6. PubMed ID: 23934108
[TBL] [Abstract][Full Text] [Related]
20. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
